A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies

To date, two chimeric antigen receptors (CAR)-T cell products from autologous T cells have been approved by The United States Food and Drug Administration (FDA). The case-by-case autologous T cell generation setting is largely considered as a pivotal restraining cause for its large-scale clinical us...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Stem Cell Res Ther
Glavni autori: Razeghian, Ehsan, Nasution, Mahyuddin K. M., Rahman, Heshu Sulaiman, Gardanova, Zhanna R., Abdelbasset, Walid Kamal, Aravindhan, Surendar, Bokov, Dmitry O., Suksatan, Wanich, Nakhaei, Pooria, Shariatzadeh, Siavash, Marofi, Faroogh, Yazdanifar, Mahboubeh, Shamlou, Somayeh, Motavalli, Roza, Khiavi, Farhad Motavalli
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2021
Teme:
Review
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8317439/
https://ncbi.nlm.nih.gov/pubmed/34321099
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13287-021-02510-7
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items